A more complete set of Phase I results for Moderna, Inc.’s vaccine mRNA-1273 against COVID-19 have shown that all 45 patients treated across all three dosing levels generated antibodies capable of neutralizing SARS-CoV-2, the novel coronavirus.
Chief medical officer Tal Zaks told Scrip that these data, published in the New England Journal of Medicine on 14...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)